Formulary Watch |

The flu program is the first in programs leveraging BioNTech’s mRNA technology for vaccines for other respiratory viruses, oncology, and genetic diseases.

Effective Jan. 1 2022, the move brings the price to 2008 levels.

Shifting cancer patients to the physician setting for administration of cancer therapies could save insurers $1.28 billion.

Keytruda plus chemotherapy reduces the risk of death by 27% in patients with triple-negative breast cancer.

People over the age 65 and those at high risk of severe COVID-19, including health care workers and those with occupational exposure, are eligible for the booster.

Biogen/Samsung Bioepis’ Byooviz is a biosimilar of Genentech’s Lucentis.

The vaccines advisory committee voted late on Friday, September 17, 2021, to provide emergency authorization of Pfizer’s COVID-19 vaccine as a booster for those over the age of 65, as well as for those at high risk of developing severe disease.

To date, Pfizer has not received reports of adverse events related to this recall, but is making the move as a precaution.

The combination of bamlanivimab/etesevimab can now be given to both treat and prevent COVID-19 infection after exposure.

Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.

Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations. This is the second approval for this mutation and the first oral therapy.

The FDA has set a Prescription Drug User Fee Act target action date of April 30, 2022.